Biomerica (BMRA) announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease, Crohn’s Disease, and Ulcerative Colitis using its proprietary inFoods Technology. These patents apply to countries under the European Patent Organization, including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations within the EPO. These recent notices of allowance and issuance of patents are a significant milestone in Biomerica’s mission to enhance patient care through personalized medical solutions. The Company is currently marketing an inFoods Technology test to treat IBS sufferers, which is already covered by 15 different patents globally. The issuance of patents in these additional disease states opens the door for Biomerica to complete development of inFoods therapeutic products to treat patients within this broader spectrum of gastrointestinal diseases.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks